Clinical Trial Search

Primary: Antibody Response to HPV Vaccine for HPV 6,11,16,18. — 1086.49; 1054.13; 745.06; 776.84 Milli Merck Units — p=>0.20

Primary: Patient Indication of Willingness to Accept the Vaccine Based on Survey — 56 Participants

Primary: Immunogenicity of a Two-dose 9-valent HPV Vaccination as Assessed by Antibody Titer — 7177.6 mMU/mL

Primary: Mother's Intention to Vaccinate Daughter Against HPV — 1.53; 1.29 units on a scale

Primary: GARDASIL Vaccination Uptake and Compliance With Second and Third Doses — 12; 12; 8; 3 participants — p=>.05

Primary: Change in Attitudes About HPV Vaccine — .16; -.08 units on a scale — p=.003

Primary: The Receipt of the First HPV Vaccination — 51; 56 percentage of participants

Primary: Overall HPV Vaccine Completion Rates — 1961; 1083 Participants

Primary: Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies — 130; 4; 190; 5 Participants

Primary: Difference in the Percentage of Adolescents Who Ever Received at Least One Dose of HPV Vaccination in the Intervention Group After the Intervention Implementation…

Primary: Human Papillomavirus or HPV-vaccine-dose Receipt — 782; 578; 408; 1056 Participants

Primary: Change From Baseline to Post Intervention to Follow-up (up to 3 Months) After the Interventions the Number of Participants Who Have Taken the HPV Vaccine — 0; 0; 0; 0…

Primary: Intention to Vaccinate Against HPV in the Next 12 Months — 3.49; 3.87; 4.16 score on a scale — p=<.02

Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…

Primary: Part 1: HPV Vaccine Knowledge (Aim 1) — 10.10; 3.19 score on a scale

Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 1440.4; 1903.7; 3861.7; 1397.5 EL.U/mL

Primary: First Dose HPV Vaccine Uptake — 118; 63; 117 Participants

Primary: Percentage of Participants Who Seroconvert to Each HPV Serotype (Types 6, 11, 16, 18) at Month 7 — 96.97; 99.05; 99.05; 99.05 percentage of participants

Primary: HPV-6 Antibody Level (Geometric Mean Titer of HPV-6) — 738.9 Milli-Merck units/milliliter (mMU/mL)

Primary: Percentage of Subjects Who Developed Antibody Response to the Vaccine. — 18; 20; 20 Participants

Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 92; 94 Participants

Primary: Count of Eligible Patients Agreeing to Receive a Dose of Vaccine — 686; 101 participants

Primary: Human Papillomavirus (HPV) Rate — 143; 136; 106; 113 participants

Primary: Attitudes — 5.61; 5.56; 5.51 score on a scale

Primary: Number of Subjects With Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above the Cut-off Value for Seroprotection — 190; 181 Participants

Primary: HPV Vaccination (≥1 Dose), 11-14 Year Olds at 12 Months — 3189; 3833; 4260 Participants

Primary: Number of Participants Who Performed HPV Self-testing Compared to the Number of Participants Who Responded to the Invitation to Come to the Hospital for Pap Testing…

Primary: Number of Participants Who Completed HPV Vaccine Series — 364; 344 Participants

Primary: Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 — 62; 27; 31; 23 Participants

Primary: Prevalence of HPV Vaccine Initiation in Cancer Survivors (Aim 1 [Survey]) — 179 Participants